Precigen Inc (PGEN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.63B
Last updated: Nov 17, 2026 at 11:06 AM ET
Precigen Inc (PGEN) Earnings: Report Dates and Results
Precigen (PGEN) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, Precigen reported EPS of $0.08, below the $0.09 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PGEN has an expected report date of Mar 23, 2027.
PGEN Earnings Call
The latest PGEN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, PGEN beat 14, missed 22 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $74.15M, up 2439.4% from $2.92M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.08 | $0.09 | $0.05 - $0.14 | -11.11% | Miss | N/A | 4 | 0 up, 0 down | Nov 4, 2026 | $74.15M |
| Jun 30, 2026 | $0.05 | -$0.02 | -$0.02 - -$0.01 | +350.00% | Beat | N/A | 3 | 1 up, 0 down | Aug 4, 2026 | $54.98M |
| Mar 31, 2026 | -$0.02 | -$0.04 | -$0.05 - -$0.03 | +50.00% | Beat | N/A | 2 | 2 up, 0 down | May 13, 2026 | $23.25M |
| Dec 31, 2025 | -$0.07 | -$0.08 | N/A | +20.29% | Beat | N/A | 2 | 0 up, 3 down | Mar 25, 2026 | $3.71M |
| Sep 30, 2025 | -$1.06 | -$0.09 | -$0.10 - -$0.09 | N/A | N/A | N/A | 2 | 0 up, 3 down | Nov 13, 2025 | $2.92M |
| Jun 30, 2025 | -$0.08 | -$0.08 | -$0.08 - -$0.08 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Aug 12, 2025 | $856000 |
| Mar 31, 2025 | -$0.18 | -$0.08 | N/A | -125.00% | Miss | N/A | N/A | 0 up, 0 down | May 14, 2025 | $1.34M |
| Dec 31, 2024 | -$0.04 | -$0.06 | -$0.07 - -$0.04 | +33.33% | Beat | N/A | 4 | N/A | Mar 19, 2025 | $473000 |
| Sep 30, 2024 | -$0.09 | -$0.09 | -$0.09 - -$0.07 | 0.00% | In line | N/A | 4 | 0 up, 1 down | Nov 14, 2024 | $953000 |
| Jun 30, 2024 | -$0.10 | -$0.09 | -$0.10 - -$0.09 | -11.11% | Miss | N/A | 5 | 0 up, 0 down | Aug 14, 2024 | $1.43M |
| Mar 31, 2024 | -$0.10 | -$0.08 | -$0.09 - -$0.08 | -25.00% | Miss | N/A | 5 | 0 up, 0 down | May 14, 2024 | $1.06M |
| Dec 31, 2023 | -$0.13 | -$0.08 | -$0.08 - -$0.07 | -62.50% | Miss | N/A | 4 | 0 up, 0 down | Mar 19, 2024 | $1.23M |
| Sep 30, 2023 | -$0.08 | -$0.08 | -$0.08 - -$0.07 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Nov 9, 2023 | $1.38M |
| Jun 30, 2023 | -$0.08 | -$0.10 | -$0.11 - -$0.09 | +20.00% | Beat | N/A | 5 | 0 up, 0 down | Aug 9, 2023 | $1.77M |
| Mar 31, 2023 | -$0.10 | -$0.09 | -$0.11 - -$0.06 | -11.11% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2023 | $1.85M |
| Dec 31, 2022 | -$0.11 | -$0.12 | -$0.12 - -$0.05 | +8.33% | Beat | N/A | 4 | 0 up, 0 down | Mar 6, 2023 | $1.76M |
| Sep 30, 2022 | -$0.04 | -$0.09 | -$0.14 - $0.32 | +55.56% | Beat | N/A | 3 | 0 up, 0 down | Nov 9, 2022 | $16.72M |
| Jun 30, 2022 | -$0.08 | -$0.14 | N/A | +42.86% | Beat | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | $2.91M |
| Mar 31, 2022 | -$0.10 | -$0.13 | -$0.15 - -$0.10 | +23.08% | Beat | N/A | 4 | 0 up, 0 down | May 9, 2022 | $5.51M |
| Dec 31, 2021 | -$0.13 | -$0.12 | -$0.18 - -$0.09 | -8.33% | Miss | N/A | 5 | 0 up, 0 down | Mar 1, 2022 | N/A |
| Sep 30, 2021 | -$0.15 | -$0.13 | -$0.18 - -$0.10 | -15.38% | Miss | N/A | 6 | N/A | Nov 8, 2021 | $3.33M |
| Jun 30, 2021 | -$0.10 | -$0.12 | -$0.15 - -$0.10 | +16.67% | Beat | N/A | 6 | N/A | Aug 9, 2021 | $3.81M |
| Mar 31, 2021 | -$0.11 | -$0.15 | -$0.19 - -$0.13 | +26.67% | Beat | N/A | 6 | N/A | May 10, 2021 | $73.60M |
| Dec 31, 2020 | -$0.23 | -$0.17 | -$0.23 - -$0.08 | -35.29% | Miss | N/A | 6 | N/A | Mar 1, 2021 | N/A |
| Sep 30, 2020 | -$0.18 | -$0.14 | -$0.20 - -$0.10 | -28.57% | Miss | N/A | 3 | N/A | Nov 9, 2020 | $23.58M |
| Jun 30, 2020 | -$0.26 | -$0.13 | -$0.24 - -$0.03 | -100.00% | Miss | N/A | 2 | N/A | Aug 10, 2020 | $30.42M |
| Mar 31, 2020 | -$0.35 | -$0.24 | -$0.24 - -$0.24 | -45.83% | Miss | N/A | 1 | N/A | May 6, 2020 | $29.84M |
| Dec 31, 2019 | -$0.28 | -$0.29 | -$0.32 - -$0.23 | +3.45% | Beat | N/A | 3 | N/A | Mar 2, 2020 | $8.36M |
| Sep 30, 2019 | -$0.35 | -$0.25 | N/A | -40.00% | Miss | N/A | N/A | N/A | Nov 12, 2019 | $18.30M |
| Jun 30, 2019 | -$0.25 | -$0.29 | N/A | +13.79% | Beat | N/A | N/A | N/A | Aug 8, 2019 | $35.99M |
| Mar 31, 2019 | -$0.40 | -$0.25 | N/A | -60.00% | Miss | N/A | N/A | N/A | May 9, 2019 | $23.34M |
| Dec 31, 2018 | -$2.59 | -$0.34 | N/A | -661.76% | Miss | N/A | N/A | N/A | Feb 28, 2019 | N/A |
| Sep 30, 2018 | -$0.44 | -$0.23 | N/A | -91.30% | Miss | N/A | N/A | N/A | Nov 8, 2018 | $32.45M |
| Jun 30, 2018 | -$0.51 | -$0.23 | N/A | -121.74% | Miss | N/A | N/A | N/A | Aug 13, 2018 | $45.27M |
| Mar 31, 2018 | -$0.32 | -$0.24 | N/A | -33.33% | Miss | N/A | N/A | N/A | May 10, 2018 | $39.67M |
| Dec 31, 2017 | -$0.09 | -$0.32 | N/A | +71.88% | Beat | N/A | N/A | N/A | Mar 1, 2018 | $426.36M |
| Sep 30, 2017 | -$0.35 | -$0.15 | N/A | -133.33% | Miss | N/A | N/A | N/A | Nov 9, 2017 | $46.02M |
| Jun 30, 2017 | -$0.23 | -$0.10 | N/A | -130.00% | Miss | N/A | N/A | N/A | Aug 9, 2017 | $54.43M |
| Mar 31, 2017 | -$0.25 | -$0.22 | N/A | -13.64% | Miss | N/A | N/A | N/A | May 10, 2017 | $53.75M |
| Dec 31, 2016 | -$0.37 | -$0.23 | N/A | -60.87% | Miss | N/A | N/A | N/A | Mar 1, 2017 | $46.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.39, after -$0.33 the year before. It was -$1.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.39 | N/A |
| Dec 31, 2024 | -$0.33 | N/A |
| Dec 31, 2023 | -$0.39 | N/A |
| Dec 31, 2022 | -$0.33 | N/A |
| Dec 31, 2021 | -$0.49 | N/A |
| Dec 31, 2020 | -$1.02 | N/A |
| Dec 31, 2019 | -$1.28 | N/A |
| Dec 31, 2018 | -$3.86 | N/A |
| Dec 31, 2017 | -$0.92 | N/A |
| Dec 31, 2016 | -$1.17 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,500 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,549 | 10 | |
| 2026Q2 | Jun 30, 2026 | 4,573 | 10 | |
| 2026Q1 | Mar 31, 2026 | 3,721 | 8 | |
| 2025Q4 | Dec 31, 2025 | 4,612 | 10 | |
| 2025Q3 | Sep 30, 2025 | 4,491 | 9 | |
| 2024Q4 | Dec 31, 2024 | 4,584 | 11 | |
| 2024Q2 | Jun 30, 2024 | 2,005 | 8 |
2026Q3 Earnings Call
Opening remarks
Steven Harasym Company Representative Thank you, operator, and thank you to everyone joining us for Precigen's Third Quarter 2026 Financial Results and Business Update Call. Joining me today are Helen Sabzevari, our President and Chief Executive Officer; Phil Tennant, our Chief Commercial Officer; Harry Thomasian, our Chief Financial Officer; and Rutul Shah, our Chief Operating Officer. Helen will begin with our business highlights. Phil will review commercial progress, and Harry will discuss our financial results for the quarter. Rutul will be available for Q&A as well. Before we begin, I remind everyone that today's discussion will include forward-looking statements based on our current expectations and beliefs. Actual results could differ materially because of risks and uncertainties described in the forward-looking statement slide of this presentation and our most recent SEC filings. With that, I will turn the call over to Dr. Sabzevari. Helen?
Helen Sabzevari President and Chief Executive Officer Thank you, Steve, and thank you to everyone joining us today. The third quarter of 2026 represents another defining milestone for Precigen. Just over one year ago, we made history with the FDA approval of PAPZIMEOS, the first approved treatment for adults with recurrent respiratory papillomatosis, or RRP, in more than a century of this disease. Today, we are demonstrating what that achievement means for patients, physicians, and our business. We have moved rapidly from regulatory approval to commercial success, delivering three consecutive quarters of significant revenue growth, bringing PAPZIMEOS to major medical centers, infusion centers, and community practices across the country, achieving profitability in both the second and third quarters, and generating positive cash flow in the third quarter, ahead of our guidance. We brought in net product revenue in Q3 of $72.9 million and launch-to-date revenue of $151 million. This is the definition of execution excellence. These accomplishments reflect our paradigm-shifting approach to drug development, combining differentiated science, smart indication selection, and innovative clinical and regulatory strategies to accelerate the delivery of transformative therapies to patients. With the recent conditional approval of a competitor therapy for RRP treatment, I want to provide a perspective on Precigen's position and the continued opportunity ahead. We have always anticipated competition and incorporated it into our strategic planning, commercial modeling, and investment decisions from the outset. Our strategy was built not simply to be first, but to establish enduring leadership in RRP—and that is exactly what we have accomplished. Our leadership is built on four pillars: a first-line product defined by its efficacy, safety, durability, and ease of administration; a strong regulatory foundation; an established commercial infrastructure; and a demonstrated ability to execute. Together, these attributes have already established our position in the market, and they continue to strengthen our value proposition. First, our product.
Frequently Asked Questions About PGEN
When is Precigen's next earnings date?
Precigen's next earnings report is expected for Mar 23, 2027.
Did PGEN beat earnings estimates last quarter?
No. Precigen reported EPS of $0.08 for the quarter ended Sep 30, 2026, below the $0.09 estimate by 11.11%.
What EPS do analysts expect from PGEN next quarter?
The consensus EPS estimate for Precigen for the quarter ending Dec 31, 2026 is $0.12 from 6 analysts, with estimates from $0.11 to $0.14.
How often does PGEN beat earnings estimates?
Precigen beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +39.69%.
PGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors